<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910635</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 304801-CS13</org_study_id>
    <nct_id>NCT02910635</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Four-Period Crossover, Study to Evaluate the Effect of Volanesorsen on the QTc Interval Using a Therapeutic and Supra-Therapeutic Dose Compared With Placebo in Healthy Volunteers: a Thorough QT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the corrected QT interval (QTc) effect of
      volanesorsen (ISIS 304801) administered as a 300 mg subcutaneous (SC) therapeutic and a 300
      mg intravenous (IV; 2-hour infusion) supra-therapeutic dose relative to placebo in healthy
      adult male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2016</start_date>
  <completion_date type="Actual">December 20, 2016</completion_date>
  <primary_completion_date type="Actual">December 20, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo corrected change from baseline in QTcF (corrected Frederica's CT Interval)</measure>
    <time_frame>24 Hours</time_frame>
    <description>ECG monitoring up to 24 hours post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placebo corrected change from baseline heart rate (HR, PR and QRS)</measure>
    <time_frame>24 Hours</time_frame>
    <description>ECG monitoring 24 hours post dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Volanesorse plasma pharmacokinetics (PK)</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Area under the plasma concentration time curve from time 0 to 24 hours (AUC 0-24h)</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Abnormalities, Cardiovascular</condition>
  <arm_group>
    <arm_group_label>Volanesorsen, Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volanesorsen, Subcutaneous (SQ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intravenous (IV) single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as normal saline (0.9% Sodium Chloride)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Subcutaneous (SC) single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as normal saline (0.9% Sodium Chloride)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volanesorsen</intervention_name>
    <description>ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial</description>
    <arm_group_label>Volanesorsen, Intravenous (IV)</arm_group_label>
    <arm_group_label>Volanesorsen, Subcutaneous (SQ)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose</description>
    <arm_group_label>Moxifloxacin Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Intravenous (IV) single dose</arm_group_label>
    <arm_group_label>Placebo Subcutaneous (SC) single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have given written informed consent and be able to comply with all study
             requirements

          -  Males and females aged 18-55 at the time of informed consent

          -  Females must be non-pregnant and non-lactating surgically sterile, post-menopausal or
             if engaged in sexual relations of childbearing potential, using an acceptable
             contraceptive method

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

          -  The subject has a BMI of 19 to 32 kg/m^2 inclusive

          -  Consumption of nicotine or nicotine-containing products for at least 6 months before
             Screening

        Exclusion Criteria:

          -  History of risk factors for Torsades de Pointes, unexplained syncope, known Long QT
             Syndrome, heart failure, myocardial infarction, angina, or clinical significant
             abnormal laboratory assessments including hypokalemia, hypocalcemia, hypercalcemia, or
             hypomagnesemia

          -  Abnormal screening ECG

          -  Use of concomitant medications unless authorized by the Sponsor Medical Monitor

          -  Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
             or chronic hepatitis B

          -  Treatment with another Study Drug, biological agent, or device within one-month of
             Screening

          -  Tests positive for drugs of abuse or cotinine

          -  Considered unsuitable for inclusion by the Principal Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thorough QTc, Therapeutic dose, supra therapeutic dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

